Citalopram, QTc Prolongation, and Torsades de Pointes
- 1 January 2015
- journal article
- review article
- Published by Elsevier in Psychosomatics
- Vol. 56 (1) , 36-43
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- A Comparison of the Risk of QT Prolongation Among SSRIsAnnals of Pharmacotherapy, 2013
- Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reportsTherapeutic Advances in Drug Safety, 2013
- QTc Prolongation, Torsades de Pointes, and Psychotropic MedicationsPsychosomatics, 2013
- Citalopram, QTc Interval Prolongation, and Torsade de Pointes. How Should We Apply the Recent FDA Ruling?The American Journal of Medicine, 2012
- Distressing Adverse Events After Antidepressant Switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: Influence of Adverse Events During Initial Treatment with Citalopram on Development of Subsequent Adverse Events with an Alternative AntidepressantPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trialsBMJ Open, 2011
- Citalopram versus other antidepressants for late‐life depression: a systematic review and meta‐analysisInternational Journal of Geriatric Psychiatry, 2010
- Effect of a Serotonin Reuptake Inhibitor on Irritability, Apathy, and Psychotic Symptoms in Patients With Alzheimer's DiseaseThe Journal of Clinical Psychiatry, 2009
- BRADYCARDIA DURING CITALOPRAM TREATMENT: A CASE REPORTPharmacological Research, 1999
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981